Drug Profile
Research programme: peptide therapeutics - Janssen Biotech/PYC Therapeutics
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Janssen Biotech; Phylogica
- Developer Janssen Biotech; PYC Therapeutics
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Australia
- 04 Jan 2012 Early research in Undefined indication in Australia (unspecified route)